Abstract
Mutations affecting the epidermal growth factor receptor (EGFR) are good predictors of clinical efficacy of EGFR tyrosine kinase inhibitors (TKI) in patients with non-small cell lung cancer. Serum carcinoembryonic antigen (CEA) levels are also regarded as predictive for the efficacy of EGFR-TKI and EGFR gene mutations. This study analyzed the association between EGFR gene mutations and clinical features, including serum tumor marker levels in lung adenocarcinomas patients. A total of 70 lung adenocarcinoma patients with complete clinical data and pathological specimens were investigated. EGFR gene mutations at exons 19 and 21 were assessed. Serum tumor markers were detected by protein chip- chemiluminescence at the corresponding time, and correlations were analyzed. Mutations of the EGFR gene were detected in 27 of the 70 patients and the serum CEA and CA242 concentrations were found to be significantly associated with the incidence of EGFR gene mutations (P<0.05). The AUCs for CEA and CA242 were 0.724 (95% CI: 0.598~0.850, P<0.05) and 0.769 (95% CI: 0.523~0.800, P<0.05) respectively. Serum CEA and CA242 levels are associated with mutations of the EGFR gene in patients with lung adenocarcinomas.
Highlights
Lung cancer is one of the most common tumors, the incidence and mortality rates of male were 35.5 and 31.2 per 100, 000 people respectively, which common in female, and the incidence rate of Chinese women has risen to 21 per100, 000 people
Paez et al (2004) firstly pointed out that some gene mutation, which suggest that epidermal growth factor receptor (EGFR) mutation may be not mutations may be beneficial to the EGFR-tyrosine kinase inhibitors (TKI) efficacy. an indicator to predict the effect of EGFR-TKI
These gene mutations are more common do not benefit from EGFR-TKI if the EGFR gene have no in lung adenocarcinoma, female patients, non-smokers mutation after detection? Are there any more convenient and peoples in East Asia
Summary
Lung cancer is one of the most common tumors, the incidence and mortality rates of male were 35.5 and 31.2 per 100, 000 people respectively, which common in female, and the incidence rate of Chinese women has risen to 21 per100 000 people. In order to improve the effect of non-small cell lung cancer treatment and prolong patient survival time, new therapy way or drug is needed. Mutations affecting the epidermal growth factor receptor (EGFR) are good predictors of clinical efficacy of EGFR tyrosine kinase inhibitors (TKI) in patients with non-small cell lung cancer. Serum carcinoembryonic antigen (CEA) levels are regarded as predictive for the efficacy of EGFR-TKI and EGFR gene mutations. This study analyzed the association between EGFR gene mutations and clinical features, including serum tumor marker levels in lung adenocarcinomas patients. Results: Mutations of the EGFR gene were detected in 27 of the 70 patients and the serum CEA and CA242 concentrations were found to be significantly associated with the incidence of EGFR gene mutations (P
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
